The SMAC mimetic GDC-0152 is a direct ABCB1-ATPase activity modulator and BIRC5 expression suppressor in cancer cells

In conclusion, GDC-0152 has the potential for use in the management of cancer patients with ABCB1 and BIRC5-related drug resistance. The findings of our study provide essential information to physicians for designing a more patient-specific GDC-0152 clinical trial program in the future.PMID:38452945 | DOI:10.1016/j.taap.2024.116888

Source: Toxicology and Applied Pharmacology - March 7, 2024 Category: Toxicology Authors: I-Li Lin Yu-Ting Lin Yung-Chieh Chang Sree Karani Kondapuram Kai-Hsuan Lin Pin-Chen Chen Chung-Ying Kuo Mohane Selvaraj Coumar Chun Hei Antonio Cheung Source Type: research